Cargando…
Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)
Ticagrelor is one of the most powerful P2Y(12) inhibitor. We have recently reported that, in patients with concomitant Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing percutaneous coronary intervention (PCI), treatment with ticagrelor, as compared to...
Autores principales: | Vieceli Dalla Sega, Francesco, Fortini, Francesca, Aquila, Giorgio, Pavasini, Rita, Biscaglia, Simone, Bernucci, Davide, Del Franco, Annamaria, Tonet, Elisabetta, Rizzo, Paola, Ferrari, Roberto, Campo, Gianluca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900783/ https://www.ncbi.nlm.nih.gov/pubmed/29686623 http://dx.doi.org/10.3389/fphys.2018.00337 |
Ejemplares similares
-
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease
por: Campo, Gianluca, et al.
Publicado: (2017) -
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial
por: Biscaglia, Simone, et al.
Publicado: (2017) -
Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study
por: Cimaglia, Paolo, et al.
Publicado: (2019) -
Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease
por: Aquila, Giorgio, et al.
Publicado: (2020) -
Notch Signaling Regulates Immune Responses in Atherosclerosis
por: Vieceli Dalla Sega, Francesco, et al.
Publicado: (2019)